All In Biotech

Drug Trial Radar · NCT00567554

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,600

Actual

Start

Oct 2007

Primary completion

Aug 2011

Study completion Oct 2015

Sponsor

Lead sponsor
GBG Forschungs GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AGO Study Group
First posted
Dec 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anthracycline-taxane based chemotherapy regimens are recommended mainly by current guidelines for neoadjuvant application of systemic treatment. The addition of other cytotoxic agents, e.g. antimetabolites, vincaalkaloids, or platinum salts resulted in marginal increase in efficacy, but was associated also with an increase in toxicity. Recently, only the addition of the Her-2 antibody trastuzumab has significantly improved pathologic response rate. Therefore, two major strategies are followed in current research projects: * To improve the selection of patients according to their tumors' sensitivity to chemotherapy. * To implement small molecules with specific mechanism of action. Within the GeparQuinto trial, the first strategy is followed by: * The PREDICT substudy. A gene signature specific for the response to anthracyclines and taxanes will be prospectively evaluated for its ability to identify patients with chance higher than 50% for a pCR. The results may leed to a better risk-benefit ratio for the use of conventional chemotherapy. * Adapting further chemotherapy to the response of the tumor to the first couple of chemotherapy cycles. Based on the previous experience made by the GeparTrio study, patients not responding early have a low chance to respond with a pCR irrespective of the type of chemotherapy. So, if further chemotherapy is planned, therapy should be selected according to a favorable toxicity profile. The second strategy is followed by investigating in three parallel group comparisons the efficiency of three distinct small molecules which appear to be generally active in breast cancer: * Bevacizumab, an inhibitor of the VEGF pathway targeting tumor neo-angiogenesis. * Lapatinib, an inhibitor of the Her-1 and Her-2 receptor tyrosine kinase. * RAD001 (Everolimus), an inhibitor of the mTOR molecule, a central controller of tumor cell growth and angiogenesis and chemosensitizer. Treatment for patients participating in the GeparQuinto study will be allocated according to the Her-2 status of the tumor as well as according to the sonographic response after the first 4 cycles of treatment. Experimental therapy with bevacizumab, lapatinib, and everolimus (RAD001) will be randomly added in distinct settings.

Conditions

  • Breast Cancer

Interventions

  • epirubicin - cyclophosphamide / docetaxelDrug

  • epirubicin - cyclophosphamide / docetaxel + bevacizumabDrug

  • paclitaxelDrug

  • paclitaxel + everolimus (RAD001)Drug

  • epirubicin - cyclophosphamide / docetaxel + trastuzumabDrug

  • epirubicin - cyclophosphamide / docetaxel + lapatinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the pCR rates of neoadjuvant treatment in all 3 SettingsTime frame: 2009

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Universitätsfrauenklinik Frankfurt / Main

    Frankfurt am Main, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.